New TB Vaccines Safe, Effective for Children, Not All Forms
Two new tuberculosis vaccines demonstrated safety and immune response in a large Indian trial, but did not provide broad protection against all TB forms; notable efficacy was observed against extrapulmonary TB and in children. tuberculosis
LP(a)-Lowering Drugs Poised as Pharma’s Next Breakthrough
The next big thing in pharma over the next few years - drugs to reduce LP(a). https://t.co/2rmLcAFGp1
CDC Vaccine Panel Rules Target Lawsuit, Boost Kennedy Allies
New rules for CDC vaccine panel aim to address lawsuit, empower Kennedy’s allies https://t.co/miSg4oOYSu via @statnews
FDA Reopens Mifepristone Safety Review Amid Court Pressure
FDA is working on another safety review of abortion drug mifepristone, after a Louisiana court order/pressure from @HawleyMO - FDA in 2021 said it did not find increases in adverse events after allowing remote prescribing https://t.co/FcznZ41p45
Scientists Advance mRNA Immunotherapies for Cancer, Funding Lags
Now in addition to our @TexasChildrens @BCM_TropMed protein vaccines for global health, our scientists are refining the mRNA technology for new immunotherapies for pancreatic cancer and triple negative breast cancer, if only the grant support would hold… https://t.co/NEgq6DX4qz
Interpretability Becomes New Scalability in Synthetic Biology
One of the most clarifying conversations we've had about where biotech should go next. Krish Ramadurai of @aixventureshq argues interpretability is the new scalability, and that the founders who build mechanistic, measurable platforms will define the next era of synthetic biology. He...
AI‑Native Platforms Treat Genome Like Code, Transform Biotech
Investor Liliana Nordbakk believes the genome behaves like code and AI-native biology platforms will transform biotech. Excited to have her speaking at #SynBioBeta2026. Visit the SynBioBeta website to read the full article. https://t.co/3WOSXsz1zy
Polygenic Scores Make Parental Genetic Choices More Intentional
Parents already make genetic decisions about the traits of their kids when they select a partner. Now those choices are becoming more conscious. @herasight is building polygenic scores that predict traits and diseases across diverse ancestries. Looking forward to hearing @JonathanAnomaly...
AI Creates Hypotheses; Medra Builds Factories to Test Them
AI is generating hypotheses, Medra is building the factories that test them and deliver the life-changing discoveries:
Eli Lilly's GLP-1 Pill Ignites Rivalry with Novo
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk https://t.co/zM6udFvuNE by Kristin Jensen $LLY $NVO #obesity
B‑cell Reboot Shows Promise Across Multiple Autoimmune Diseases
More success for rebooting B cells towards cure of different autoimmune diseases beyond lupus, MS and others https://t.co/sFGMiFeiEF https://t.co/Dbvca9eox8
AI Slashes Amgen's Drug Development Timelines up to 70%
Morgan Stanley met with Amgen (biotech) management on how AI is benefiting their workflows. Key findings: - 8%: Approximate industry drug-development success rate Amgen cited as the baseline AI could help improve. - 10–14 years: Typical drug-development cycle time Amgen cited...
Beyond T(11;14): Expanding Venetoclax Use in Myeloma
Venetoclax in myeloma: t(11;14) and what else? {Commentary} [Apr 2, 2026] Catherine Pellat-Deceunynck @BloodPortfolio https://t.co/Zar26htoUT #mmsm #PrecisionMedicine https://t.co/zm0Fv6GY2l
GSK’s Leucovorin
what a timeline - Sept. 1999 - $GSK withdraws Wellcovorin (leucovorin) bc it's not selling Sept. 2025 - GSK is told by FDA to apply for a new indication for leucovorin after an FDA review of lit. March 2026 - FDA approves...
Mixed Metastatic Sites Confound Apparent Treatment Effects
Your clinical trial baseline is a mix of liver mets, lung mets, bone mets, and primary tumors. You compare it to post-treatment samples from different sites. The "treatment effects" you find will mostly be tissue site differences. https://t.co/0PyjMM2Znl
Needham’s M&A Note Erroneously Flags LLY‑VKTX Deal
1000% certain ,Needham made a mistake in their "The Biotech M&A Landscape" note -(or maybe Viking got bought and they are the only ones that know it lol) calling out a few M&A targets and inadvertently mentioning a $LLY $VKTX...
Nasal Anti‑CD3 Cuts Neuroinflammation in Long‑COVID Mice
Our new preprint by @peowenlu @SaefIzzy @weinerlabhms and colleagues shows that nasal anti-CD3 monoclonal antibody treatment can reduce neuroinflammation in a mouse model of Long COVID, even when administered at 4 weeks after infection 🧠 https://t.co/P8FZA2XA37
Innate Pharma Poised for Breakthrough with Astra Phase III
Innate Pharma $IPH. €110m market cap, decent net cash position (runway for another few Qs), and several key drug programs reaching critical milestones. The most significant is a Phase III trial (monalizumab in lung cancer) run with Astra $AZN, with...
Next-Gen Yellow Fever Vaccine Shows Promise in Mid
My comments and interview with @Medscape Next-Gen Yellow Fever Vaccine Hits the Mark in Mid-Stage Trial https://t.co/kFfGH4c5gt
View mRNA‑CRISPR as Molecular Surgery, Not Drugs
What if we started thinking of mRNA-CRISPR gene editing as molecular surgery, not as a pharmaceutical product? Excellent @nytimes guest essay ⤵️ https://t.co/S61XwNRVZF
Rapamycin Fails to Slow Epigenetic Aging, Sinclair Concedes
David Sinclair says rapamycin had no measurable effect on slowing or reversing epigenetic aging in humans. This was a drug most of the longevity community supported. He was even a believer of it. It was found to extend lifespan in: • Inbred lab animals •...
Weight‑loss Drug Semaglutide Cuts Depression Risk by 42%
A 10-year study finds weight-loss drugs lower the risk of #depression and anxiety. Published in The Lancet Psychiatry, the #research revealed a 42% lower risk of #mentalhealth hospitalisation during periods of semaglutide use. https://t.co/CphnQl0Khx
Regenerative Medicine Needs Data Over Hype
I recently had the opportunity to sit down with Scott Carney for a wide-ranging conversation on regenerative medicine, stem cells, peptides, and the growing gap between scientific promise and clinical reality. In the conversation, we dig into: – Why stem cell therapies...
Engineered Bacteria Consume Tumor Core, Overcoming Drug Barriers
JUST IN: Scientists built bacteria that EATS cancer from the inside out. The future of cancer treatment isn't a drug. It's a living organism that devours tumors from the inside. Here's how it works: Solid tumors have a dead center. No oxygen. No...
SIRT6 Gene Therapy Remains Safe, Effective in Aged Beagles
Genflow sees sustained safety and efficacy in SIRT6 beagle trial 🐶 “Genflow Biosciences reported that three-month follow-up data from its SLAB trial in aged beagles show sustained safety and efficacy of its SIRT6 centenarian gene therapy, with no adverse events and...
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/18HJ5kRuNj
Phase
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
Single Gene Therapy Dose Eradicates Brain Tumors in Mice
GENE THERAPY SAFELY ERADICATES BRAIN TUMOURS IN MICE A single dose of an innovative gene therapy could eliminate hard-to-treat brain tumours and prevent them from coming back, according to a pre-clinical trial in mice, reported in Nature. “More than 80 per cent...
Dietary Amino Acid Restriction Shows Promise Against Pediatric Brain Cancer
Can rebooting the diet, eliminating 2 essential amino acids, help treat an aggressive brain cancer in children? mechanism and potential established from experimental model https://t.co/wmAFM2ErRB https://t.co/PAOr5SL30y
Statins Cut Mortality for Over‑80s Without Added Risks
Should people over age 80 use statins? The answer is increasingly: YES. A recent study found that patients over 80 on statins had a one-third reduction in mortality. Perhaps more telling, people who stopped their statins appeared to have a 1/3...
Flu Shot Cuts Alzheimer’s Risk Up to 55%
💉 Want to reduce the risk of Alzheimer' by 55%? A simple flu shot at the dosage recommended by the CDC for those 65 and older should do the trick. With 165,000 people in the study, they also...
AI Drug Discovery: Hype Overwhelms Real Clinical Success
AI Drug Discovery – Revolution or Expensive Illusion? | Ep. 978 https://t.co/YLQ8QNlnWv [ 00:34 ] Billions into AI drug discovery [ 01:04 ] AI doesn’t cure diseases [ 01:38 ] Expensive illusion vs reality [ 02:23 ] Original pitch inefficiency problem [ 03:48 ] Only 10...
New Catalyst Quickly Builds Complex Molecules for Drug Discovery
A new catalytic method enables rapid, selective synthesis of branched molecules from simple, inexpensive reagents, streamlining early drug discovery and expanding access to complex molecular architectures. drugdiscovery
Two Cancer Startups Secure $237M for Antibody Innovations
A couple cool cancer drug startups profiled this week in TR. Sidewinder Therapeutics with $137M for bispecific ADCs https://t.co/tJcQwI7C4U and Stipple Bio with $100M for novel targets for antibody drugs. https://t.co/rbXkuaRpoe
Wedbush Flags One NKTR Dosing Interval as Unviable
You'll never guess which of these two dosing intervals Wedbush says "may not be viable" for $NKTR Rezpeg moving forward. Won't mince words - This firm is responsible for the worst sellside work I've ever seen. Sorry to be harsh,...
Novo Undercuts Lilly with Pricier Wegovy; Insmed Braces for Flop
Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure https://t.co/jN9GuuOf4s $NVO $LLY $INSM $VRTX $BIIB
2024 NIA‑AA Definition Connects Biomarkers Directly to Care
The 2024 NIA-AA biological definition of Alzheimer’s disease: linking biomarkers to clinical practice https://t.co/00cP1mXXHR https://t.co/VQ59YeIUR1
Genomics Predicts Individual Weight Loss From GLP‑1 Drugs
Genomics of GLP-1 drug response and side effects With genomic and demographic data it's possible to predict magnitude of weight loss response @23andMe https://t.co/iAS2Fjjxig https://t.co/AXsWnZw2Ub
Genomic Drivers of Venetoclax Resistance in T(11;14) Myeloma
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) [Apr 2, 2026] @MKaddouraMD et al. @lbaughn @BloodPortfolio https://t.co/qmI6giPG6K #mmsm #PrecisionMedicine https://t.co/hpwUcavTg9
RFK Jr. Pushes to Overturn Peptide Ban, Officials Dispute Claims
RFK Jr. May Reverse a Peptide Ban He Calls “Illegal.” Former FDA Officials Say He Mischaracterized Their Work. https://t.co/glqreTHvKA https://t.co/Vi4OTryX3p
Lymph-Node CD8+ T Cells Amplify PD-1 Blockade in GI Cancer
PD-1 antibody-bound progenitor-exhausted CD8+ T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer https://t.co/VKoxzy6oUq https://t.co/cQG2sLWtL2
NRH Prevents Age‑related Hearing Loss via Sirt3‑mediated Ferroptosis Suppression
NRH attenuates age-related hearing loss by suppressing cochlear ferroptosis and cellular senescence via Sirt3 activation https://t.co/MOqQblWYNM https://t.co/uhSMXRIxDK
Controversial Drugs Once Feared, Now Offer Hope
A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope Another wonderful piece from @Jasonmmast https://t.co/zOvLrdAPKi via @statnews
Know the FDA Process: Key to Biotech Investing
Investors should understand the #FDA regulatory process well. Here is a quick summary At each step investors should ask themselves if the company is developing things in a way that will satisfy the FDA Until a drug is approved the FDA is...
GSK's Depemokimab Gains Chinese Approval for Nasal Polyps
#GSK Exdensur (depemokimab) approved in China for treating Chronic Rhinosinusitis with Nasal Polyps, following the ANCHOR trials.
Startup Pitches Brainless Human Clones for Organ Harvesting
Big news about a startup called R3 Bio that plans to create brainless human clones for the sole purpose of harvesting organs when people need them. They are just pitching the idea to investors now, but it is pretty wild (if...
Lithium Reverses ApoE4 Cellular Deficits, Merits AD Trials
https://t.co/r6JzHA1RxM with ApoE4/E4 from a sporadic Alzheimer's disease patient "Given the drug's demonstrated efficacy in reversing ApoE4-driven cellular vulnerabilities, lithium salt warrants further investigation for the treatment of AD." https://t.co/r6JzHA1RxM https://t.co/v2lE0XhN7n
Prediction Markets Could Overtake Biotech Stocks for Phase‑3 Bets
I think that one day soon that prediction markets are going to replace biotech stocks for how investors play key readouts...especially wrt larger companies. For example, if Novartis has a big phase 3, isn't it more interesting and efficient to...
Targeting Liver ApoE Boosts Bone Healing in the Elderly
Neutralizing hepatic apolipoprotein E enhances aged bone fracture healing "Our work here identifies novel liver-to-bone cross-talk and a noninvasive, translatable therapeutic intervention for aged bone regeneration" https://t.co/KSzvkKOzZt https://t.co/1p0cXQlalT
Α‑Eleostearic Acid Acts as Senolytic via Ferroptosis
α-eleostearic acid as a senolytic via ferroptosis. Found in high concentrations in Tung oil (which is toxic) and in small amounts in Bitter Melon oil. https://t.co/FSCix3OZtD